A recent study published in the Cancer Journal established that chemosensitivity assay profiling is a promising tool which can be used for guiding treatment in advanced pancreatic adenocarcinoma (PDAC) patients.
This prospective study aimed to establish chemosensitivity assay as a cutting edge approach to guide treatment in patients with metastatic PDAC. The study included 70 metastatic PDAC patients who were yet to receive either G/nab-P or FOLFIRINOX at a 1:1 ratio. For this, 6ml of peripheral blood was drawn from the patients at baseline and once the disease progression occured, isolation of circulating tumor and invasive cells (CTICs) was done, followed by gene-expression profiling, and the assay to gather information about effective and ineffective chemotherapeutic agents.
Chemosensitivity assay rightly predicted that the patients who were treated with effective chemotherapeutic agents had significantly longer median progression-free survival and median overall survival, than an ineffective regimen.
Thus, chemosensitivity assay profiling holds a lot of promise in advanced PDAC treatment therapy.